Action ANEB ANEBULO PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Anebulo Pharmaceuticals, Inc.

Actions

ANEB

US0345691036

Marché Fermé - Nasdaq
Autres places de cotation
 17:59:12 10/05/2024 		Varia. 5j. Varia. 1 janv.
3,01 USD +0,33% Graphique intraday de Anebulo Pharmaceuticals, Inc. +2,03% +24,38%
13/02 Anebulo Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 décembre 2023 CI
2023 Anebulo Pharmaceuticals, Inc. publie ses résultats pour le premier trimestre clos le 30 septembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Appoints New CEO
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Anebulo Pharmaceuticals : Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates - Form 8-K
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer
Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer
Anebulo Pharmaceuticals, Inc. Announces Sandra A. Gardiner Resigns as Acting Chief Financial Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ANEB
  4. Actualités Anebulo Pharmaceuticals, Inc.
  5. Autres langues